anti-amyloid beta antibodies

Anti-amyloid beta antibodies are a class of monoclonal antibodies designed to target and clear amyloid-beta (Aβ) aggregates, including soluble oligomers, protofibrils, and insoluble plaques, from the brains of patients with Alzheimer's disease. By binding to specific conformations or epitopes of the Aβ peptide, these immunotherapies promote the clearance of amyloid deposits via microglial phagocytosis or direct disassembly, thereby aiming to slow cognitive and functional decline. Key approved therapies in this class include lecanemab (Leqembi) and donanemab (Kisunla), which have demonstrated the ability to significantly reduce amyloid plaque burden in clinical trials, supporting the amyloid cascade hypothesis of Alzheimer's disease.

Other names

Aβ-mAbsamyloid-beta-targeting monoclonal antibodiesanti-Aβ antibodiesanti-Aβ monoclonal antibodiesanti-amyloid antibodiesanti-amyloid-beta monoclonal antibodiesanti-amyloid-β antibodiesanti-amyloid-β monoclonal antibodies